High Growth Rate of Benign Thyroid Nodules Bearing RET/PTC Rearrangements

Context:Benign thyroid nodules display a broad range of behaviors from a stationary size to a progressive growth. The RET/PTC oncogene has been documented in a fraction of benign thyroid nodules, besides papillary thyroid carcinomas, and it might therefore influence their growth.Objective:The aim of...

Full description

Saved in:
Bibliographic Details
Published inThe journal of clinical endocrinology and metabolism Vol. 96; no. 6; pp. E916 - E919
Main Authors Sapio, Maria Rosaria, Guerra, Anna, Marotta, Vincenzo, Campanile, Elisabetta, Formisano, Raffaele, Deandrea, Maurilio, Motta, Manuela, Limone, Paolo Piero, Fenzi, Gianfranco, Rossi, Guido, Vitale, Mario
Format Journal Article
LanguageEnglish
Published United States Oxford University Press 01.06.2011
Subjects
Online AccessGet full text
ISSN0021-972X
1945-7197
1945-7197
DOI10.1210/jc.2010-1599

Cover

Abstract Context:Benign thyroid nodules display a broad range of behaviors from a stationary size to a progressive growth. The RET/PTC oncogene has been documented in a fraction of benign thyroid nodules, besides papillary thyroid carcinomas, and it might therefore influence their growth.Objective:The aim of the present work was to evaluate whether RET/PTC in benign thyroid nodules associates with a different nodular growth rate.Study Design:In this prospective multicentric study, 125 subjects with benign nodules were included. RET rearrangements were analyzed in cytology samples; clinical and ultrasonographic nodule characteristics were assessed at the start and at the end of the study.Results: RET/PTC was present in 19 nodules. The difference between the mean baseline nodular volume of the RET/PTC− and RET/PTC+ nodules was not significant. After 36 months of follow-up, the RET/PTC+ group (n = 16) reached a volume higher than the RET/PTC− group (n = 90) (5.04 ± 2.67 vs. 3.04 ± 2.26 ml; P = 0.0028). We calculated the monthly change of nodule volumes as a percentage of baseline. After a mean follow-up of 36.6 months, the monthly volume increase of nodules bearing a RET rearrangement was 4.3-fold that of nodules with wild-type RET (1.83 ± 1.2 vs. 0.43 ± 1.0% of baseline volume; P < 0.0001).Conclusions:Benign thyroid nodules bearing RET rearrangements grow more rapidly than those with wild-type RET. Searching for RET rearrangements in benign thyroid nodules might be useful to the clinician in choosing the more appropriate and timely therapeutic option.
AbstractList Context:Benign thyroid nodules display a broad range of behaviors from a stationary size to a progressive growth. The RET/PTC oncogene has been documented in a fraction of benign thyroid nodules, besides papillary thyroid carcinomas, and it might therefore influence their growth.Objective:The aim of the present work was to evaluate whether RET/PTC in benign thyroid nodules associates with a different nodular growth rate.Study Design:In this prospective multicentric study, 125 subjects with benign nodules were included. RET rearrangements were analyzed in cytology samples; clinical and ultrasonographic nodule characteristics were assessed at the start and at the end of the study.Results: RET/PTC was present in 19 nodules. The difference between the mean baseline nodular volume of the RET/PTC− and RET/PTC+ nodules was not significant. After 36 months of follow-up, the RET/PTC+ group (n = 16) reached a volume higher than the RET/PTC− group (n = 90) (5.04 ± 2.67 vs. 3.04 ± 2.26 ml; P = 0.0028). We calculated the monthly change of nodule volumes as a percentage of baseline. After a mean follow-up of 36.6 months, the monthly volume increase of nodules bearing a RET rearrangement was 4.3-fold that of nodules with wild-type RET (1.83 ± 1.2 vs. 0.43 ± 1.0% of baseline volume; P < 0.0001).Conclusions:Benign thyroid nodules bearing RET rearrangements grow more rapidly than those with wild-type RET. Searching for RET rearrangements in benign thyroid nodules might be useful to the clinician in choosing the more appropriate and timely therapeutic option.
Context:Benign thyroid nodules display a broad range of behaviors from a stationary size to a progressive growth. The RET/PTC oncogene has been documented in a fraction of benign thyroid nodules, besides papillary thyroid carcinomas, and it might therefore influence their growth.Objective:The aim of the present work was to evaluate whether RET/PTC in benign thyroid nodules associates with a different nodular growth rate.Study Design:In this prospective multicentric study, 125 subjects with benign nodules were included. RET rearrangements were analyzed in cytology samples; clinical and ultrasonographic nodule characteristics were assessed at the start and at the end of the study.Results: RET/PTC was present in 19 nodules. The difference between the mean baseline nodular volume of the RET/PTC− and RET/PTC+ nodules was not significant. After 36 months of follow-up, the RET/PTC+ group (n = 16) reached a volume higher than the RET/PTC− group (n = 90) (5.04 ± 2.67 vs. 3.04 ± 2.26 ml; P = 0.0028). We calculated the monthly change of nodule volumes as a percentage of baseline. After a mean follow-up of 36.6 months, the monthly volume increase of nodules bearing a RET rearrangement was 4.3-fold that of nodules with wild-type RET (1.83 ± 1.2 vs. 0.43 ± 1.0% of baseline volume; P < 0.0001).Conclusions:Benign thyroid nodules bearing RET rearrangements grow more rapidly than those with wild-type RET. Searching for RET rearrangements in benign thyroid nodules might be useful to the clinician in choosing the more appropriate and timely therapeutic option.
Benign thyroid nodules display a broad range of behaviors from a stationary size to a progressive growth. The RET/PTC oncogene has been documented in a fraction of benign thyroid nodules, besides papillary thyroid carcinomas, and it might therefore influence their growth.CONTEXTBenign thyroid nodules display a broad range of behaviors from a stationary size to a progressive growth. The RET/PTC oncogene has been documented in a fraction of benign thyroid nodules, besides papillary thyroid carcinomas, and it might therefore influence their growth.The aim of the present work was to evaluate whether RET/PTC in benign thyroid nodules associates with a different nodular growth rate.OBJECTIVEThe aim of the present work was to evaluate whether RET/PTC in benign thyroid nodules associates with a different nodular growth rate.In this prospective multicentric study, 125 subjects with benign nodules were included. RET rearrangements were analyzed in cytology samples; clinical and ultrasonographic nodule characteristics were assessed at the start and at the end of the study.STUDY DESIGNIn this prospective multicentric study, 125 subjects with benign nodules were included. RET rearrangements were analyzed in cytology samples; clinical and ultrasonographic nodule characteristics were assessed at the start and at the end of the study.RET/PTC was present in 19 nodules. The difference between the mean baseline nodular volume of the RET/PTC- and RET/PTC+ nodules was not significant. After 36 months of follow-up, the RET/PTC+ group (n = 16) reached a volume higher than the RET/PTC- group (n = 90) (5.04 ± 2.67 vs. 3.04 ± 2.26 ml; P = 0.0028). We calculated the monthly change of nodule volumes as a percentage of baseline. After a mean follow-up of 36.6 months, the monthly volume increase of nodules bearing a RET rearrangement was 4.3-fold that of nodules with wild-type RET (1.83 ± 1.2 vs. 0.43 ± 1.0% of baseline volume; P < 0.0001).RESULTSRET/PTC was present in 19 nodules. The difference between the mean baseline nodular volume of the RET/PTC- and RET/PTC+ nodules was not significant. After 36 months of follow-up, the RET/PTC+ group (n = 16) reached a volume higher than the RET/PTC- group (n = 90) (5.04 ± 2.67 vs. 3.04 ± 2.26 ml; P = 0.0028). We calculated the monthly change of nodule volumes as a percentage of baseline. After a mean follow-up of 36.6 months, the monthly volume increase of nodules bearing a RET rearrangement was 4.3-fold that of nodules with wild-type RET (1.83 ± 1.2 vs. 0.43 ± 1.0% of baseline volume; P < 0.0001).Benign thyroid nodules bearing RET rearrangements grow more rapidly than those with wild-type RET. Searching for RET rearrangements in benign thyroid nodules might be useful to the clinician in choosing the more appropriate and timely therapeutic option.CONCLUSIONSBenign thyroid nodules bearing RET rearrangements grow more rapidly than those with wild-type RET. Searching for RET rearrangements in benign thyroid nodules might be useful to the clinician in choosing the more appropriate and timely therapeutic option.
Benign thyroid nodules display a broad range of behaviors from a stationary size to a progressive growth. The RET/PTC oncogene has been documented in a fraction of benign thyroid nodules, besides papillary thyroid carcinomas, and it might therefore influence their growth. The aim of the present work was to evaluate whether RET/PTC in benign thyroid nodules associates with a different nodular growth rate. In this prospective multicentric study, 125 subjects with benign nodules were included. RET rearrangements were analyzed in cytology samples; clinical and ultrasonographic nodule characteristics were assessed at the start and at the end of the study. RET/PTC was present in 19 nodules. The difference between the mean baseline nodular volume of the RET/PTC- and RET/PTC+ nodules was not significant. After 36 months of follow-up, the RET/PTC+ group (n = 16) reached a volume higher than the RET/PTC- group (n = 90) (5.04 ± 2.67 vs. 3.04 ± 2.26 ml; P = 0.0028). We calculated the monthly change of nodule volumes as a percentage of baseline. After a mean follow-up of 36.6 months, the monthly volume increase of nodules bearing a RET rearrangement was 4.3-fold that of nodules with wild-type RET (1.83 ± 1.2 vs. 0.43 ± 1.0% of baseline volume; P < 0.0001). Benign thyroid nodules bearing RET rearrangements grow more rapidly than those with wild-type RET. Searching for RET rearrangements in benign thyroid nodules might be useful to the clinician in choosing the more appropriate and timely therapeutic option.
Author Marotta, Vincenzo
Motta, Manuela
Fenzi, Gianfranco
Rossi, Guido
Vitale, Mario
Campanile, Elisabetta
Deandrea, Maurilio
Guerra, Anna
Sapio, Maria Rosaria
Formisano, Raffaele
Limone, Paolo Piero
Author_xml – sequence: 1
  givenname: Maria Rosaria
  surname: Sapio
  fullname: Sapio, Maria Rosaria
  organization: 1Dipartimento di Endocrinologia ed Oncologia Molecolare e Clinica (M.R.S., A.G., V.M., E.C., R.F., G.F., M.V.), Università Federico II, 80131 Naples, Italy
– sequence: 2
  givenname: Anna
  surname: Guerra
  fullname: Guerra, Anna
  organization: 1Dipartimento di Endocrinologia ed Oncologia Molecolare e Clinica (M.R.S., A.G., V.M., E.C., R.F., G.F., M.V.), Università Federico II, 80131 Naples, Italy
– sequence: 3
  givenname: Vincenzo
  surname: Marotta
  fullname: Marotta, Vincenzo
  organization: 1Dipartimento di Endocrinologia ed Oncologia Molecolare e Clinica (M.R.S., A.G., V.M., E.C., R.F., G.F., M.V.), Università Federico II, 80131 Naples, Italy
– sequence: 4
  givenname: Elisabetta
  surname: Campanile
  fullname: Campanile, Elisabetta
  organization: 1Dipartimento di Endocrinologia ed Oncologia Molecolare e Clinica (M.R.S., A.G., V.M., E.C., R.F., G.F., M.V.), Università Federico II, 80131 Naples, Italy
– sequence: 5
  givenname: Raffaele
  surname: Formisano
  fullname: Formisano, Raffaele
  organization: 1Dipartimento di Endocrinologia ed Oncologia Molecolare e Clinica (M.R.S., A.G., V.M., E.C., R.F., G.F., M.V.), Università Federico II, 80131 Naples, Italy
– sequence: 6
  givenname: Maurilio
  surname: Deandrea
  fullname: Deandrea, Maurilio
  organization: 2Struttura complessa di Endocrinologia (M.D., P.P.L.), Presidio Ospedaliero “Umberto I,” Ordine Mauriziano, 10128 Torino, Italy
– sequence: 7
  givenname: Manuela
  surname: Motta
  fullname: Motta, Manuela
  organization: 3Struttura complessa di Anatomia Patologica (M.M.), Presidio Ospedaliero “Umberto I,” Ordine Mauriziano, 10128 Torino, Italy
– sequence: 8
  givenname: Paolo Piero
  surname: Limone
  fullname: Limone, Paolo Piero
  organization: 2Struttura complessa di Endocrinologia (M.D., P.P.L.), Presidio Ospedaliero “Umberto I,” Ordine Mauriziano, 10128 Torino, Italy
– sequence: 9
  givenname: Gianfranco
  surname: Fenzi
  fullname: Fenzi, Gianfranco
  organization: 1Dipartimento di Endocrinologia ed Oncologia Molecolare e Clinica (M.R.S., A.G., V.M., E.C., R.F., G.F., M.V.), Università Federico II, 80131 Naples, Italy
– sequence: 10
  givenname: Guido
  surname: Rossi
  fullname: Rossi, Guido
  organization: 4Dipartimento di Biologia e Patologia Cellulare e Molecolare (G.R.), Università Federico II, 80131 Naples, Italy
– sequence: 11
  givenname: Mario
  surname: Vitale
  fullname: Vitale, Mario
  email: mavitale@unina.it
  organization: 1Dipartimento di Endocrinologia ed Oncologia Molecolare e Clinica (M.R.S., A.G., V.M., E.C., R.F., G.F., M.V.), Università Federico II, 80131 Naples, Italy
BackLink https://www.ncbi.nlm.nih.gov/pubmed/21411555$$D View this record in MEDLINE/PubMed
BookMark eNp1kU1LAzEQhoMotn7cPMuCBy-uZjab3c1RS_0AUSkVvIU0nW1TtklNdhH_vam2l4KnmXl5ZpiZ94jsW2eRkDOg15ABvVno64wCTYELsUf6IHKeliDKfdKnNINUlNlHjxyFsKAU8pyzQ9LLIAfgnPfJ06OZzZMH777aeTJSLSauTu7QmplNxvNv78w0eXHTrsEQZeWNnSWj4fjmbTxIRrH2ys5wibYNJ-SgVk3A0008Ju_3w_HgMX1-fXga3D6nmnHaphqhniIvaxpLoRBFUWsUvIiyYJoLBRkvSohSXQrUWnBFGeQxqWo6ydkxufybu_Lus8PQyqUJGptGWXRdkFVRsYoWLIvkxQ65cJ23cTnJoMhzVkBVRup8Q3WTJU7lypul8t9y-6MIZH-A9i4Ej7XUplWtcbb1yjQSqFwbIRdaro2QayNi09VO03buP_jmKNet_iN_HWY_3buSrQ
CitedBy_id crossref_primary_10_1186_1471_2482_13_S2_S49
crossref_primary_10_1016_j_beem_2014_01_011
crossref_primary_10_1530_EJE_11_0499
crossref_primary_10_1002_cncr_29044
crossref_primary_10_1186_1471_2482_13_S2_S44
crossref_primary_10_1016_j_ecl_2018_10_003
crossref_primary_10_1186_1471_2482_13_S2_S41
crossref_primary_10_1089_thy_2012_0614
crossref_primary_10_1007_s15006_013_2404_9
crossref_primary_10_1530_EJE_14_0930
crossref_primary_10_2217_bmm_13_67
crossref_primary_10_1016_j_ijsu_2014_05_045
crossref_primary_10_1016_j_ijsu_2014_05_043
crossref_primary_10_1038_s41598_019_44931_8
crossref_primary_10_1007_s12020_012_9843_4
crossref_primary_10_1089_thy_2013_0610
crossref_primary_10_1007_s00060_014_0002_9
crossref_primary_10_1089_thy_2013_0235
crossref_primary_10_1089_thy_2013_0278
crossref_primary_10_1111_cen_13591
crossref_primary_10_1038_nrc3431
crossref_primary_10_1016_j_ctrv_2015_06_002
crossref_primary_10_1186_s13044_023_00161_9
crossref_primary_10_1038_nrendo_2011_142
crossref_primary_10_3390_cells10051082
crossref_primary_10_1007_s40618_014_0128_z
crossref_primary_10_1016_j_critrevonc_2013_12_007
crossref_primary_10_1186_1471_2482_13_S2_S37
crossref_primary_10_1210_jc_2011_3106
crossref_primary_10_1016_j_jasc_2015_01_001
crossref_primary_10_1007_s15015_014_0001_0
crossref_primary_10_1080_14737140_2016_1238764
crossref_primary_10_1530_JOE_17_0266
crossref_primary_10_1586_14789450_2015_1062369
crossref_primary_10_2174_0929867327666200214125712
crossref_primary_10_1089_thy_2014_0338
crossref_primary_10_1089_thy_2017_0318
crossref_primary_10_1155_2023_7951942
crossref_primary_10_4158_EP12304_OR
crossref_primary_10_1111_cen_12875
crossref_primary_10_1530_ERC_16_0372
crossref_primary_10_1038_nrendo_2017_24
crossref_primary_10_3390_ijms18040806
crossref_primary_10_1007_s12020_015_0773_9
crossref_primary_10_1111_cen_12194
Cites_doi 10.1128/MCB.21.13.4177-4187.2001
10.1507/endocrj.K10E-229
10.1210/er.2002-0016
10.1038/sj.onc.1207790
10.1111/j.1365-2265.1992.tb02898.x
10.1210/jc.2003-031870
10.1128/MCB.16.5.2151
10.1016/S1074-7613(00)80165-X
10.1210/jc.2001-011762
10.1210/jcem.83.3.4615
10.1146/annurev.immunol.19.1.397
10.7326/0003-4819-122-1-199501010-00001
10.1038/sj.onc.1200206
10.1038/labinvest.3780377
10.1007/BF03350907
10.1172/JCI200522758
ContentType Journal Article
Copyright Copyright © 2011 by The Endocrine Society 2011
Copyright © 2011 by The Endocrine Society
Copyright_xml – notice: Copyright © 2011 by The Endocrine Society 2011
– notice: Copyright © 2011 by The Endocrine Society
DBID AAYXX
CITATION
CGR
CUY
CVF
ECM
EIF
NPM
7QP
7T5
7TM
H94
K9.
7X8
DOI 10.1210/jc.2010-1599
DatabaseName CrossRef
Medline
MEDLINE
MEDLINE (Ovid)
MEDLINE
MEDLINE
PubMed
Calcium & Calcified Tissue Abstracts
Immunology Abstracts
Nucleic Acids Abstracts
AIDS and Cancer Research Abstracts
ProQuest Health & Medical Complete (Alumni)
MEDLINE - Academic
DatabaseTitle CrossRef
MEDLINE
Medline Complete
MEDLINE with Full Text
PubMed
MEDLINE (Ovid)
AIDS and Cancer Research Abstracts
ProQuest Health & Medical Complete (Alumni)
Immunology Abstracts
Calcium & Calcified Tissue Abstracts
Nucleic Acids Abstracts
MEDLINE - Academic
DatabaseTitleList
AIDS and Cancer Research Abstracts
MEDLINE - Academic
MEDLINE
Database_xml – sequence: 1
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 2
  dbid: EIF
  name: MEDLINE
  url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search
  sourceTypes: Index Database
DeliveryMethod fulltext_linktorsrc
Discipline Medicine
EISSN 1945-7197
EndPage E919
ExternalDocumentID 21411555
10_1210_jc_2010_1599
10.1210/jc.2010-1599
Genre Research Support, Non-U.S. Gov't
Multicenter Study
Journal Article
GroupedDBID ---
-~X
.55
.XZ
08P
0R~
18M
1TH
29K
2WC
34G
354
39C
4.4
48X
53G
5GY
5RS
5YH
8F7
AABZA
AACZT
AAIMJ
AAPQZ
AAPXW
AARHZ
AAUAY
AAVAP
AAWTL
ABBLC
ABDFA
ABEJV
ABGNP
ABJNI
ABLJU
ABMNT
ABNHQ
ABOCM
ABPMR
ABPPZ
ABPQP
ABPTD
ABQNK
ABVGC
ABWST
ABXVV
ACGFO
ACGFS
ACPRK
ACUTJ
ACYHN
ADBBV
ADGKP
ADGZP
ADHKW
ADQBN
ADRTK
ADVEK
AELWJ
AEMDU
AENEX
AENZO
AETBJ
AEWNT
AFCHL
AFFNX
AFFZL
AFGWE
AFOFC
AFRAH
AFXAL
AGINJ
AGKRT
AGQXC
AGUTN
AHMBA
AHMMS
AJEEA
ALMA_UNASSIGNED_HOLDINGS
APIBT
ARIXL
ASPBG
ATGXG
AVWKF
AZFZN
BAWUL
BAYMD
BCRHZ
BEYMZ
BSWAC
BTRTY
C45
CDBKE
CS3
D-I
DAKXR
DIK
E3Z
EBS
EJD
EMOBN
ENERS
F5P
FECEO
FHSFR
FLUFQ
FOEOM
FOTVD
FQBLK
GAUVT
GJXCC
GX1
H13
HZ~
H~9
KBUDW
KOP
KQ8
KSI
KSN
L7B
M5~
MHKGH
MJL
N9A
NLBLG
NOMLY
NOYVH
NVLIB
O9-
OAUYM
OBH
OCB
ODMLO
OFXIZ
OGEVE
OHH
OJZSN
OK1
OPAEJ
OVD
OVIDX
P2P
P6G
REU
ROX
ROZ
TEORI
TJX
TLC
TR2
TWZ
VVN
W8F
WOQ
X7M
YBU
YFH
YHG
YOC
YSK
ZY1
~02
~H1
AAYXX
ABXZS
ADNBA
AEMQT
AEOTA
AFYAG
AGORE
ALXQX
CITATION
NU-
.GJ
3O-
7X7
88E
8FI
8FJ
AAJQQ
AAKAS
AAPGJ
AAQQT
AAUQX
AAWDT
AAYJJ
ABDPE
ABUWG
ACFRR
ACVCV
ACZBC
ADMTO
ADZCM
AERZD
AFFQV
AFKRA
AGMDO
AI.
AJDVS
APJGH
AQDSO
AQKUS
AVNTJ
BENPR
BPHCQ
BVXVI
CCPQU
CGR
CUY
CVF
ECM
EIF
EIHJH
FEDTE
FYUFA
HMCUK
HVGLF
IAO
IHR
INH
ITC
J5H
M1P
MBLQV
N4W
NPM
OBFPC
PHGZT
PQQKQ
PROAC
PSQYO
TMA
UKHRP
VH1
WHG
X52
ZGI
ZXP
7QP
7T5
7TM
AEHZK
H94
K9.
7X8
ID FETCH-LOGICAL-c350t-ce1fde57f03509aee96fce9561fd93c59a125671e95f79ecc95a0314cc98f0b43
ISSN 0021-972X
1945-7197
IngestDate Sun Sep 28 16:07:35 EDT 2025
Fri Sep 19 20:53:53 EDT 2025
Thu Apr 03 07:00:45 EDT 2025
Tue Jul 01 00:49:52 EDT 2025
Thu Apr 24 23:05:29 EDT 2025
Fri Feb 07 10:35:23 EST 2025
IsPeerReviewed true
IsScholarly true
Issue 6
Language English
LinkModel OpenURL
MergedId FETCHMERGED-LOGICAL-c350t-ce1fde57f03509aee96fce9561fd93c59a125671e95f79ecc95a0314cc98f0b43
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 14
content type line 23
PMID 21411555
PQID 3164436187
PQPubID 2046206
ParticipantIDs proquest_miscellaneous_868380632
proquest_journals_3164436187
pubmed_primary_21411555
crossref_citationtrail_10_1210_jc_2010_1599
crossref_primary_10_1210_jc_2010_1599
oup_primary_10_1210_jc_2010-1599
ProviderPackageCode CITATION
AAYXX
PublicationCentury 2000
PublicationDate 20110601
2011-06-01
2011-Jun
PublicationDateYYYYMMDD 2011-06-01
PublicationDate_xml – month: 06
  year: 2011
  text: 20110601
  day: 01
PublicationDecade 2010
PublicationPlace United States
PublicationPlace_xml – name: United States
– name: Washington
PublicationTitle The journal of clinical endocrinology and metabolism
PublicationTitleAlternate J Clin Endocrinol Metab
PublicationYear 2011
Publisher Oxford University Press
Publisher_xml – name: Oxford University Press
References Melillo (2020071616354365000_B14) 2005; 115
Unger (2020071616354365000_B10) 2004; 89
La Rosa (2020071616354365000_B19) 1995; 122
Mellado (2020071616354365000_B13) 2001; 19
Hegedüs (2020071616354365000_B1) 2003; 24
Borrello (2020071616354365000_B3) 1996; 16
Ishizaka (2020071616354365000_B4) 1991; 6
Santoro (2020071616354365000_B2) 1996; 12
Castellone (2020071616354365000_B15) 2004; 23
Elisei (2020071616354365000_B5) 2001; 86
Melillo (2020071616354365000_B9) 2001; 21
Costante (2020071616354365000_B16) 2004; 27
Zlotnik (2020071616354365000_B12) 2000; 12
Reverter (2020071616354365000_B20) 1992; 36
(2020071616354365000_B7) 2002
Corvi (2020071616354365000_B11) 2001; 81
Marotta (2020071616354365000_B8) 2010; 57
Castro (2020071616354365000_B17) 2002; 87
Bounacer (2020071616354365000_B6) 1997; 15
Papini (2020071616354365000_B18) 1998; 83
References_xml – volume: 21
  start-page: 4177
  year: 2001
  ident: 2020071616354365000_B9
  article-title: Docking protein FRS2 links the protein tyrosine kinase RET and its oncogenic forms with the mitogen-activated protein kinase signaling cascade.
  publication-title: Mol Cell Biol
  doi: 10.1128/MCB.21.13.4177-4187.2001
– volume: 57
  start-page: 1081
  year: 2010
  ident: 2020071616354365000_B8
  article-title: Growing thyroid nodules with benign histology and RET rearrangement.
  publication-title: Endocr J
  doi: 10.1507/endocrj.K10E-229
– volume: 86
  start-page: 3211
  year: 2001
  ident: 2020071616354365000_B5
  article-title: RET/PTC rearrangements in thyroid nodules: studies in irradiated and not irradiated, malignant and benign thyroid lesions in children and adults.
  publication-title: J Clin Endocrinol Metab
– volume: 24
  start-page: 102
  year: 2003
  ident: 2020071616354365000_B1
  article-title: Management of simple nodular goiter: current status and future perspectives.
  publication-title: Endocr Rev
  doi: 10.1210/er.2002-0016
– volume: 23
  start-page: 5958
  year: 2004
  ident: 2020071616354365000_B15
  article-title: Functional expression of the CXCR4 chemokine receptor is induced by RET/PTC oncogenes and is a common event in human papillary thyroid carcinomas.
  publication-title: Oncogene
  doi: 10.1038/sj.onc.1207790
– volume: 36
  start-page: 25
  year: 1992
  ident: 2020071616354365000_B20
  article-title: Suppressive therapy with levothyroxine for solitary thyroid nodules.
  publication-title: Clin Endocrinol (Oxf)
  doi: 10.1111/j.1365-2265.1992.tb02898.x
– start-page: 7
  volume-title: Fine-needle aspiration cytology (FNAC). Guidelines for the management of thyroid cancer in adults
  year: 2002
  ident: 2020071616354365000_B7
– volume: 89
  start-page: 4272
  year: 2004
  ident: 2020071616354365000_B10
  article-title: Heterogeneity in the distribution of RET/PTC rearrangements within individual post-Chernobyl papillary thyroid carcinomas.
  publication-title: J Clin Endocrinol Metab
  doi: 10.1210/jc.2003-031870
– volume: 12
  start-page: 1821
  year: 1996
  ident: 2020071616354365000_B2
  article-title: Development of thyroid papillary carcinomas secondary to tissue-specific expression of the RET/PTC1 oncogene in transgenic mice.
  publication-title: Oncogene
– volume: 16
  start-page: 2151
  year: 1996
  ident: 2020071616354365000_B3
  article-title: The full oncogenic activity of Ret/ptc2 depends on tyrosine 539, a docking site for phospholipase Cγ.
  publication-title: Mol Cell Biol
  doi: 10.1128/MCB.16.5.2151
– volume: 12
  start-page: 121
  year: 2000
  ident: 2020071616354365000_B12
  article-title: Chemokines: a new classification system and their role in immunity.
  publication-title: Immunity
  doi: 10.1016/S1074-7613(00)80165-X
– volume: 87
  start-page: 4154
  year: 2002
  ident: 2020071616354365000_B17
  article-title: Effectiveness of thyroid hormone suppressive therapy in benign solitary thyroid nodules: a meta-analysis.
  publication-title: J Clin Endocrinol Metab
  doi: 10.1210/jc.2001-011762
– volume: 83
  start-page: 780
  year: 1998
  ident: 2020071616354365000_B18
  article-title: Long-term changes in nodular goiter: a 5-year prospective randomized trial of levothyroxine suppressive therapy for benign cold thyroid nodules.
  publication-title: J Clin Endocrinol Metab
  doi: 10.1210/jcem.83.3.4615
– volume: 19
  start-page: 397
  year: 2001
  ident: 2020071616354365000_B13
  article-title: Chemokine signaling and functional responses: the role of receptor dimerization and TK pathway activation.
  publication-title: Annu Rev Immunol
  doi: 10.1146/annurev.immunol.19.1.397
– volume: 122
  start-page: 1
  year: 1995
  ident: 2020071616354365000_B19
  article-title: Levothyroxine and potassium iodide are both effective in treating benign solitary solid cold nodules of the thyroid.
  publication-title: Ann Intern Med
  doi: 10.7326/0003-4819-122-1-199501010-00001
– volume: 15
  start-page: 1263
  year: 1997
  ident: 2020071616354365000_B6
  article-title: High prevalence of activating ret proto-oncogene rearrangements, in thyroid tumors from patients who had received external radiation.
  publication-title: Oncogene
  doi: 10.1038/sj.onc.1200206
– volume: 81
  start-page: 1639
  year: 2001
  ident: 2020071616354365000_B11
  article-title: Frequent RET rearrangements in thyroid papillary microcarcinoma detected by interphase fluorescence in situ hybridization.
  publication-title: Lab Invest
  doi: 10.1038/labinvest.3780377
– volume: 27
  start-page: 31
  year: 2004
  ident: 2020071616354365000_B16
  article-title: Slow growth of benign thyroid nodules after menopause: no need for long-term thyroxine suppressive therapy in post-menopausal women.
  publication-title: J Endocrinol Invest
  doi: 10.1007/BF03350907
– volume: 6
  start-page: 1667
  year: 1991
  ident: 2020071616354365000_B4
  article-title: Detection of retTPC/PTC transcripts in thyroid adenomas and adenomatous goiter by an RT-PCR method.
  publication-title: Oncogene
– volume: 115
  start-page: 1068
  year: 2005
  ident: 2020071616354365000_B14
  article-title: The RET/PTC-RAS-BRAF linear signaling cascade mediates the motile and mitogenic phenotype of thyroid cancer cells.
  publication-title: J Clin Invest
  doi: 10.1172/JCI200522758
SSID ssj0014453
Score 2.2882686
Snippet Context:Benign thyroid nodules display a broad range of behaviors from a stationary size to a progressive growth. The RET/PTC oncogene has been documented in a...
Benign thyroid nodules display a broad range of behaviors from a stationary size to a progressive growth. The RET/PTC oncogene has been documented in a...
SourceID proquest
pubmed
crossref
oup
SourceType Aggregation Database
Index Database
Enrichment Source
Publisher
StartPage E916
SubjectTerms Adult
Aged
Benign
Blotting, Southern
Cytology
Female
Gene Rearrangement
Growth rate
Humans
Male
Middle Aged
Nodules
Oncogene Proteins, Fusion - genetics
Papillary thyroid carcinoma
Prospective Studies
Proto-Oncogene Proteins c-ret - genetics
Ret protein
Thyroid
Thyroid gland
Thyroid Nodule - diagnostic imaging
Thyroid Nodule - genetics
Thyroid Nodule - pathology
Ultrasonography
Title High Growth Rate of Benign Thyroid Nodules Bearing RET/PTC Rearrangements
URI https://www.ncbi.nlm.nih.gov/pubmed/21411555
https://www.proquest.com/docview/3164436187
https://www.proquest.com/docview/868380632
Volume 96
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
journalDatabaseRights – providerCode: PRVBFR
  databaseName: Free Medical Journals Online
  customDbUrl:
  eissn: 1945-7197
  dateEnd: 20240930
  omitProxy: true
  ssIdentifier: ssj0014453
  issn: 0021-972X
  databaseCode: DIK
  dateStart: 19970101
  isFulltext: true
  titleUrlDefault: http://www.freemedicaljournals.com
  providerName: Flying Publisher
– providerCode: PRVFQY
  databaseName: GFMER Free Medical Journals
  customDbUrl:
  eissn: 1945-7197
  dateEnd: 20240930
  omitProxy: true
  ssIdentifier: ssj0014453
  issn: 0021-972X
  databaseCode: GX1
  dateStart: 19960101
  isFulltext: true
  titleUrlDefault: http://www.gfmer.ch/Medical_journals/Free_medical.php
  providerName: Geneva Foundation for Medical Education and Research
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1bb9MwFLbKkBAviDuFgfwAT1VgaWwnfuRStIE2oalDe4sc29E6dc6UpkLsL_EnOad20lR03F6i1HWT9Jwv52KfCyEveWzB7kxNVDBjIpB-SVTEhkXSGp2BRhJqlRR2eCT2T9inU346GPzoRS0tm-K1vtqaV_I_XIUx4Ctmyf4DZ7uLwgCcA3_hCByG41_xGIM0cPXoW3M2OlZ-w_-dddhqc3r2va5mZnRUmeXcLmBY-Ui7yRTu92WKhFV1jakFF205p9ZIRej0Kkp0yZPWmQqEjFuXbbqwDYBo3pYhxJUadTmrQhLQTI2Oq4Xygcw-ymdp69qv5DrXjcLUqvFW7NcZgNBdVf2tEeVmPuZ5MseCwLZpVH-tIu7FVP0uB7IvnzFgJF01WAft5EWyZDxKYx_F28ps3wU3YLMvgCcyFj1lDh_lVkUBni4qCr0K7ovAppNrhdiFKW6feIPcHKdCYLuMDwefuy0rxkLJ0_AXQpYFpkj1f71h_2zkVP7i2qxMnOldcif4JvStB9o9MrDuPrl1GKIvHpADxBv1eKOIN1qV1OONBrzRgDca8EYBb28AbXQTbQ_JycfJ9P1-FFpxRDrhe02kbVway9MSN6KlslaKUltMii6NTDSXCgxlkcYwVKYSxILkChsjwElW7hUseUR2XOXsE0JToUuuWaLAV2CqyLIyEbHgcs-WqbFMDsmoJVCuQ516bJcyz9FfBXLm5zpHcuZIziF51c2-9PVZrplHgdbXTYn8lN2WEXl4yRZ5EoPDAA-YpXCF7msQwbivppytlos8E1mSgak_HpLHnn_dfcYxA5eL86d_vv0zcnv9yuySnaZe2udg8DbFixXQfgJmZKbq
linkProvider Flying Publisher
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=High+Growth+Rate+of+Benign+Thyroid+Nodules+Bearing+RET%2FPTC+Rearrangements&rft.jtitle=The+journal+of+clinical+endocrinology+and+metabolism&rft.au=Sapio%2C+Maria+Rosaria&rft.au=Guerra%2C+Anna&rft.au=Marotta%2C+Vincenzo&rft.au=Campanile%2C+Elisabetta&rft.date=2011-06-01&rft.pub=Oxford+University+Press&rft.issn=0021-972X&rft.eissn=1945-7197&rft.volume=96&rft.issue=6&rft.spage=E916&rft.epage=E919&rft_id=info:doi/10.1210%2Fjc.2010-1599&rft.externalDocID=10.1210%2Fjc.2010-1599
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0021-972X&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0021-972X&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0021-972X&client=summon